Phreesia, Inc. (NYSE:PHR – Get Rating) General Counsel Allison C. Hoffman sold 649 shares of the company in a transaction on Wednesday, January 18. The shares sold at an average price of $36.07 and the total transaction value was her $23,409.43. Following the closing of the transaction, General Counsel now owns her 129,507 shares in the company, valued at her $4,671,317.49. The sale was disclosed in SEC filings available at this link.
Frecia stock up 2.5%
→ Market Wizard’s #1 Strategy for 2023 – Get Early Access Now (From Legacy Research)
NYSE:PHR rose $0.86 to reach $35.25 in Friday noon trading. 401,429 shares were traded against an average volume of 363,018 shares. Phreesia, Inc. has a 12-month low of $13.19 and a 12-month high of $36.44. The 50-day moving average for this business is $30.30 and the 200-day moving average is $26.80. The company has a debt to equity ratio of 0.01, a quick ratio of 3.94 and a current ratio of 3.94. The stock has a market cap of $1.86 billion, a PE ratio of -9.71 and a beta of 0.60.
Phreesia (NYSE:PHR – Get Rating) reported final results on Thursday, Dec. 8. The company reported quarterly EPS ($0.76), beating analyst consensus expectations ($0.88) by $0.12. The company’s earnings for the quarter were $73.1 million, compared to analyst estimates of $71.16 million. Phreesia had a net profit margin of 70.36% and a return on equity of 50.32%. On average, equity analysts expect Phreesia, Inc. to post earnings per share of -3.43 for the current year.
Wall Street Analyst Predicts Growth
Many equity analysts comment on stocks. Citigroup upgraded Freesia’s stock from a ‘neutral’ rating to a ‘buy’ rating and set a price target at $40.00 on him in its research notes on Tuesday, Dec. 13. Piper Sandler raised his price target on Phreesia stock from her $33.00 to her $37.00 in a research report on Friday, Dec. 9. SVB Leerink raised its price target on Phreesia shares from $34.00 to $39.00, giving the stock an “outperform” rating in its research report on Thursday, January 5. Needham & Company LLC raised its price target on Phreesia stock from $35.00 to $40.00 in its research report on Wednesday, January 4, giving the stock a Buy rating. Finally, in its research report on Friday, December 9, Royal Bank of Canada raised its price target on Frecia shares from $22.00 to $26.00, giving the stock a ‘Sector Performing’ rating. Two research analysts rated the stock with a hold rating and 11 assigned a buy rating to the company. According to MarketBeat, Phreesia’s current consensus rating is “moderate buy” with a consensus target price of $36.29.
institution inflow and outflow
Many hedge funds and other institutional investors have recently changed their stock positions. FourThought Financial LLC raised his Phreesia holding by 16.4% in the third quarter. FourThought Financial LLC now owns 3,081 shares worth $79,000 after purchasing 434 more shares during the previous quarter. Assetmark Inc. increased his Phreesia holding by 42.2% in the second quarter. Assetmark Inc. now owns 1,685 shares worth $42,000 after purchasing an additional 500 shares during the previous quarter. US Bancorp DE increased his Phreesia holding by 6.6% in the second quarter. US Bancorp DE now owns 8,270 shares of the company worth $207,000 after purchasing an additional 509 shares during the previous quarter. Barclays PLC increased his Phreesia holding by 11.0% in the third quarter. Barclays PLC now owns 6,184 shares worth $158,000 after purchasing an additional 613 shares during the previous quarter. Finally, Arizona State Retirement System increased its Phreesia holding by 6.6% in the second quarter. Arizona State Retirement System now owns 13,192 shares worth $330,000 after purchasing an additional 815 shares during the last quarter. Hedge funds and other institutional investors own 92.23% of the company’s shares.
Frecia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the US and Canada. Its Phreesia platform offers a suite of solutions for managing the patient onboarding process and an integrated payment solution for processing patient payments.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Before you think about Phreesia, you’ll want to hear this.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Phreesia wasn’t on the list.
Phreesia is currently rated as a ‘moderate buy’ among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here